0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-3218.58%PremiumJul 19, 2024Expiry Date7.27Intrinsic Value100Multiplier-4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Trevena Stock Discussion
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with central nervous system (CNS) disorders, has recently announced a amendment to its March 2022 ex-US royalty-based financing agreement with R-Bridge Healthcare Fund, L.P. (R-Bridge). This development repr...
Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
$Trevena(TRVN.US)$ 🚀🚀🚀🚀
Waiting game….
Trevena, Inc., a biopharmaceutical company listed on the Nasdaq under the ticker symbol TRVN, has announced compelling preclinical data from two collaborative research efforts aimed at understanding the efficacy of their novel therapeutic candidate, TRV045. These studies focus on chronic neuropathic pain and epilepsy, two complex cen...
Not gonna buy this lol.
High risk low reward.
🔥Definitely seeing a bounce.
🔥OVERSOLD!!!
🔥SIGNIFICANT Anti-Seizure Activity in Epilepsy Models!!!
No comment yet